


Claims


- 5 1. A compound of formula (I)



wherein

10

ring A is selected from the group consisting of:



- 15 R^1 is selected from the group consisting of H, F, Cl, Br, CN, -OH, C_{1-4} -alkyl, -O-(C_{1-4} -alkyl), $-(CH_2)_m-COOH$, $-(CH_2)_m-C(=O)-O-(C_{1-4}-alkyl)$, -C(=O)-heterocyclyl, $-(CH_2)_m-C(=O)-NH_2$, $-(CH_2)_m-C(=O)-NH-(C_{1-4}-alkyl)$, $-(CH_2)_m-C(=O)-N(C_{1-4}-alkyl)_2$, -C(=O)-NH- C_{3-6} -cycloalkyl, -C(=O)-NH-heterocyclyl, $-(CH_2)_m-NH-C(=O)-(C_{1-3}-alkyl)$, $-N(C_{1-3}-alkyl)-C(=O)-(C_{1-4}-alkyl)$, $-N(C_{1-3}-alkyl)-C(=O)-NH_2$, -NH-C(=O)-NH- C_{1-4} -alkyl, heterocyclyl and phenyl,
- 20

wherein each alkyl group or sub-group is optionally substituted with 1 or more F atoms or with one OH or -O-(C_{1-3} -alkyl) group; and

- 25 wherein each heterocyclyl is selected from the group consisting of azetidiny, imidazolidiny, piperidinyl, piperidinyl, tetrahydropyranyl and morpholinyl and is

- 115 -

optionally substituted with one or two groups independently selected from the group consisting of oxo, C₁₋₃-alkyl, -C(=O)-CH₃ and -C(=O)-cyclopropyl; and

wherein multiple R¹ may be identical or different, if n is 2; and

5

n is an integer selected from 1 and 2; and

m is an integer selected from 0, 1 and 2; and

10 wherein in any definition mentioned hereinbefore, if not specified otherwise, any alkyl group or sub-group may be straight-chained or branched and is optionally substituted with 1 or more F atoms,

or a salt thereof.

15

2. The compound of formula (I) according to claim 1, wherein

R¹ is selected from the group consisting of:

20 H, F, Cl, -OH, C₁₋₄-alkyl, -O-(C₁₋₂-alkyl), -(CH₂)_m-COOH, -(CH₂)_m-C(=O)-O-(C₁₋₂-alkyl),
-C(=O)-heterocyclyl, -(CH₂)_m-C(=O)-NH₂, -(CH₂)_m-C(=O)-NH-(C₁₋₄-alkyl), -(CH₂)_m-
C(=O)-N(CH₃)(C₁₋₃-alkyl), -C(=O)-NH-cyclopropyl, -C(=O)-NH-heterocyclyl,
-(CH₂)_m-NH-C(=O)-(C₁₋₃-alkyl), -N(C₁₋₂-alkyl)-C(=O)-(C₁₋₂-alkyl), -N(C₁₋₂-alkyl)-C(=O)-
25 NH₂, -NH-C(=O)-NH-(C₁₋₂-alkyl), heterocyclyl and phenyl,

25

wherein each alkyl group or sub-group is optionally substituted with 1 to 3 F atoms or with one OH or -O-(C₁₋₂-alkyl) group; and

30 wherein each heterocyclyl is selected from the group consisting of azetidiny, imidazolidiny, piperidinylpiperidinyl, tetrahydropyranyl and morpholinyl and is optionally substituted with one or two groups independently selected from the group consisting of oxo, C₁₋₂-alkyl, -C(=O)-CH₃ and -C(=O)-cyclopropyl; and

- 116 -

wherein m is 0 or 1; and

wherein multiple R¹ may be identical or different, if n is 2;

5 or a salt thereof.

3. The compound of formula (I) according to claim 2, wherein

10 R¹ is selected from the group consisting of:

H, F, -OH, -CH₃, -CF₃, -O-CH₃, -COOH, -(CH₂)_m-C(=O)-O-CH₃, -(CH₂)_m-C(=O)-NH₂,
-C(=O)-NH-(C₁₋₃-alkyl), -(CH₂)-C(=O)-N(CH₃)₂, -(CH₂)-C(=O)-N(CH₃)(CH₂CH₃),
-C(=O)-NH-cyclopropyl, 1-(cyclopropylcarbonyl)-piperidin-4-yl and 3-methyl-2-oxo-
imidazolidin-1-yl,

15

wherein each ethyl group or sub-group is optionally substituted in position 2 with
one F atom, one OH or one -O-CH₃ group; and

20

wherein each propyl group or sub-group is optionally substituted in position 2 or
3 with 1 to 3 F atoms; and

wherein m is 0 or 1; and


25 wherein, if n is 2, multiple R¹ may be identical or different and the second R¹ group is
selected from the group consisting of F, CH₃, CF₃ and phenyl.
or a salt thereof.

4. The compound of formula (I) according to claim 1, wherein

30

ring A is

- 117 -



R¹ is selected from the group consisting of H, F, -OH, C₁₋₄-alkyl, -O-(C₁₋₄-alkyl),
 -(CH₂)_m-COOH, -(CH₂)_m-C(=O)-O-(C₁₋₄-alkyl), -C(=O)-heterocyclyl, -(CH₂)_m-
 5 C(=O)-NH₂, -(CH₂)_m-C(=O)-NH-(C₁₋₄-alkyl), -(CH₂)_m-C(=O)-N(C₁₋₄-alkyl)₂, -C(=O)-
 NH-C₃₋₆-cycloalkyl, -C(=O)-NH-heterocyclyl, -(CH₂)_m-NH-C(=O)-(C₁₋₃-alkyl),
 -N(C₁₋₃-alkyl)-C(=O)-(C₁₋₄-alkyl), -N(C₁₋₃-alkyl)-C(=O)-NH₂, -NH-C(=O)-NH-(C₁₋₄-
 alkyl), heterocyclyl and phenyl,

10 wherein each alkyl group or sub-group is optionally substituted with 1 or more
 F atoms or with one OH or -O-(C₁₋₃-alkyl) group; and

wherein each heterocyclyl is selected from the group consisting of azetidiny, imidazolidiny, piperidiny, tetrahydropyranyl and morpholiny and is optionally
 15 substituted with one or two groups independently selected from the group
 consisting of oxo, C₁₋₃-alkyl, -C(=O)-CH₃ and -C(=O)-cyclopropyl; and

wherein multiple R¹ may be identical or different, if n is 2; and

20 n is an integer selected from 1 and 2; and

m is an integer selected from 0 and 1; and

or a salt thereof.

25

5. The compound of formula (I) according to claim 4, wherein

R¹ is selected from the group consisting of:

30 H, -OH, C₁₋₂-alkyl, -O-(C₁₋₂-alkyl), -(CH₂)_m-COOH, -(CH₂)_m-C(=O)-O-(C₁₋₂-alkyl),
 -C(=O)-heterocyclyl, -(CH₂)_m-C(=O)-NH₂, -(CH₂)_m-C(=O)-NH-(C₁₋₄-alkyl), -(CH₂)_m-

- 118 -

$C(=O)-N(C_{1-2}\text{-alkyl})_2$, $-C(=O)-NH-C_{3-6}\text{-cyclopropyl}$, $-C(=O)-NH\text{-heterocyclyl}$, $-(CH_2)_m-NH-C(=O)-(C_{1-3}\text{-alkyl})$, $-N(CH_3)-C(=O)-(C_{1-2}\text{-alkyl})$, $-N(CH_3)-C(=O)-NH_2$, $-NH-C(=O)-NH-(C_{1-3}\text{-alkyl})$, heterocyclyl and phenyl,


5 wherein each alkyl group or sub-group is optionally substituted with 1 to 3 F atoms or with one OH or $-O-CH_3$ group; and

 wherein each heterocyclyl is selected from the group consisting of azetidiny, imidazolidiny, tetrahydropyrany and morpholiny and is optionally substituted
10 with one or two groups independently selected from the group consisting of oxo, $C_{1-3}\text{-alkyl}$ and $-C(=O)-CH_3$; and

 wherein, if n is 2, multiple R^1 may be identical or different, the second R^1 group is selected from the group consisting of CH_3 , CF_3 and phenyl;

15 or a salt thereof.

6. The compound of formula (I) according to claim 1, wherein
20 ring A is



R^1 is selected from the group consisting of H, F, Cl, -OH, $-O-(C_{1-4}\text{-alkyl})$, $-C(=O)\text{-heterocyclyl}$, $-(CH_2)_m-C(=O)-NH_2$, $-(CH_2)_m-C(=O)-NH-(C_{1-4}\text{-alkyl})$, $-(CH_2)_m-C(=O)-N(C_{1-4}\text{-alkyl})_2$, $-(CH_2)_m-NH-C(=O)-(C_{1-3}\text{-alkyl})$ and $-N(C_{1-3}\text{-alkyl})-C(=O)-(C_{1-4}\text{-alkyl})$,
25

 wherein each alkyl group or sub-group is optionally substituted with 1 or more F atoms or with one OH or $-O-(C_{1-3}\text{-alkyl})$ group; and

30

- 119 -

wherein each heterocyclyl is selected from the group consisting of azetidiny, imidazolidiny, piperidiny, tetrahydropyranyl and morpholiny and is optionally substituted with one oxo or C₁₋₃-alkyl group; and

5 wherein, if n is 2, multiple R¹ may be identical or different and the second R¹ group is F; and


n is an integer selected from 1 and 2; and

10 m is an integer selected from 0 and 1; and

or a salt thereof.

15 7. The compound of formula (I) according to claim 1, wherein

ring A is



20 R¹ is selected from the group consisting of H, -(CH₂)_m-COOH, -(CH₂)_m-C(=O)-O-(C₁₋₄-alkyl), -C(=O)-heterocyclyl, -(CH₂)_m-C(=O)-NH₂, -(CH₂)_m-C(=O)-NH-(C₁₋₄-alkyl) and -(CH₂)_m-C(=O)-N(C₁₋₄-alkyl)₂,

25 wherein each alkyl group or sub-group is optionally substituted with 1 or more F atoms or with one OH or -O-(C₁₋₃-alkyl) group; and

wherein each heterocyclyl is selected from the group consisting of azetidiny, imidazolidiny, piperidiny, tetrahydropyranyl and morpholiny and is optionally substituted with one oxo or C₁₋₃-alkyl group; and

30

wherein multiple R¹ may be identical or different, if n is 2; and

- 120 -

n is 1; and

m is an integer selected from 0 and 1; and


5

or a salt thereof.

8. The compound of formula (I) according to claim 1, wherein

10

ring A is



15 R^1 is selected from the group consisting of H, F, Cl, Br, CN, -OH, C_{1-4} -alkyl, -O-(C_{1-4} -alkyl), -C(=O)-NH₂, -C(=O)-NH-(C_{1-4} -alkyl), -C(=O)-N(C_{1-4} -alkyl)₂ and heterocyclyl,

wherein each alkyl group or sub-group is optionally substituted with 1 or more F atoms or with one OH or -O-(C_{1-3} -alkyl) group; and

20 wherein each heterocyclyl is selected from the group consisting of azetidiny, and piperidiny, and is optionally substituted with one C_{1-3} -alkyl, -C(=O)-CH₃ or -C(=O)-cyclopropyl group; and

25 wherein, if n is 2, multiple R^1 may be identical or different and the second R^1 group is selected from the group consisting of F and CH₃; and






n is an integer selected from 1 and 2; and

or a salt thereof.


30

9. The compound of formula (I) according to claim 1 selected from the group consisting of:


5




- 122 -




,




,



,




,




,


- 123 -




,




,



,



and



5

,

or a salt thereof.

10. A pharmaceutically acceptable salt of a compound according to any one of claims 1 to 9.

10

- 124 -

11. A compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof for use as a medicament.
12. A compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, NASH (non-alcoholic steatohepatitis), pulmonary fibrosis, retinopathy, nephropathy or stroke.
13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, optionally together with one or more inert carriers and/or diluents.
14. A method for treating a disease or condition which is mediated by inhibiting the activity of AOC3, comprising administering a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof to a patient in need thereof.
15. A pharmaceutical composition comprising one or more compounds according to one or more of the claims 1 to 9 or a pharmaceutically acceptable salt thereof, and one or more additional therapeutic agents, optionally together with one or more inert carriers and/or diluents.